1. Home
  2. VINP vs STTK Comparison

VINP vs STTK Comparison

Compare VINP & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vinci Partners Investments Ltd.

VINP

Vinci Partners Investments Ltd.

N/A

Current Price

$9.03

Market Cap

601.4M

Sector

Finance

ML Signal

N/A

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

N/A

Current Price

$5.77

Market Cap

652.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VINP
STTK
Founded
2009
2016
Country
Brazil
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
601.4M
652.4M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
VINP
STTK
Price
$9.03
$5.77
Analyst Decision
Buy
Strong Buy
Analyst Count
6
12
Target Price
$14.41
★ $15.40
AVG Volume (30 Days)
114.8K
★ 1.2M
Earning Date
11-12-2026
11-09-2026
Dividend Yield
★ 6.77%
N/A
EPS Growth
N/A
★ 53.02
EPS
★ N/A
N/A
Revenue
N/A
★ $1,000,000.00
Revenue This Year
$16.59
N/A
Revenue Next Year
$14.07
N/A
P/E Ratio
$24.41
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$8.91
$1.72
52 Week High
$13.61
$8.33

Technical Indicators

Market Signals
Indicator
VINP
STTK
Relative Strength Index (RSI) 33.11 47.91
Support Level N/A $5.19
Resistance Level $10.17 $7.66
Average True Range (ATR) 0.50 0.37
MACD -0.21 0.03
Stochastic Oscillator 5.54 60.69

Price Performance

Historical Comparison
VINP
STTK

About VINP Vinci Partners Investments Ltd.

Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: